Hypofractionated Versus Conventional Fractionated Radiotherapy for Patients with Triple Negative Breast Cancer: A Single Institution Randomized Trial

• Fatma Gharib

  Department of Clinical Oncology, Faculty of Medicine, Tanta University, Egypt

• Rana Ali El Falah

  Department of Clinical Oncology, Faculty of Medicine, Tanta University, Egypt

• Amr S. Ghobara

  Department of Surgery, Faculty of Medicine, Tanta University, Egypt

• Sherehan Moeness ElShishtawy

  Department of Surgery, Faculty of Medicine, Tanta University, Egypt

• Radwa A. Awad

  Department of Clinical Oncology, Faculty of Medicine, Tanta University, Egypt

Introduction: Delivering hypofractionated radiotherapy schedules for patients with breast cancer is a growing interest. The current study aimed to determine whether hypofractionated radiotherapy is as effective and safe as conventional fractionated radiotherapy for patients with triple negative breast cancer, irrespective of lymph node status or surgical type.

Methods: The current study is a randomized, open-label trial. A total of 148 female participants with non-metastatic triple negative breast cancer (TNBC) were recruited from January 2019 to December 2023. Eligible participants were randomly assigned (1:1) for hypofractionated schedule or conventional radiotherapy schedule. The trial included all nonmetastatic TNBC eligible to adjuvant radiotherapy due to positively involved lymph nodes or high-risk features of the primary tumor. The 3- year Loco-regional recurrence free survival (RFS) was the primary end point.

Results: At a median follow-up of 24 months, seven (5.3%) patients had developed locoregional recurrence, all of them in hypofractionated radiotherapy (RT) arm. The 3-year Loco-regional RFS rate was significantly higher in conventional RT arm compared to the hypofractionated RT arm (p <0.001). The 3-year distant metastases free survival was not significantly differed in the two groups (p =0.121). The 3-year overall survival was 90.4%, with no significant difference between the groups (p= 0.091).

Conclusion: The effectiveness of hypofractionated radiotherapy for disease control of triple-negative disease, irrespective of lymph node status or type of surgical interference remains questionable.

Venigalla S, Guttmann DM, Jain V, Sharma S, Freedman GM, Shabason JE. Trends and patterns of utilization of hypofractionated postmastectomy radiotherapy: a National Cancer Database analysis. Clin Breast Cancer 2018; 18: e899-908.

Lee SF, Kennedy SKF, Caini S, Wong HCY, Yip PL, Poortmans PM, et al. Randomised controlled trials on radiation dose fractionation in breast cancer: systematic review and meta-analysis with emphasis on side effects and cosmesis. BMJ 2024; 386: e079089.

Smith BD, Bentzen SM, Correa CR, Hahn CA, Hardenbergh PH, Ibbott GS, et al. Fractionation for whole breast irradiation: an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Int J Radiat Oncol Biol Phys 2011; 81: 59.

Smith BD, Bellon JR, Blitzblau R, Freedman G, Haffty B, Hahn C, et al. Radiation therapy for the whole breast: Executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline. Pract Radiat Oncol 2018; 8: 145.

Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bliss JM, et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomized trial. Lancet Oncol 2008; 9: 331-41.

Bentzen SM, Agrawal RK, Aird EG, Barrett JM, Barrett-Lee PJ, Bentzen SM, et al. The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomized trial. Lancet 2008; 371: 1098-107.

Wang SL, Fang H, Song YW, Wang WH, Hu C, Liu YP, et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomized, non-inferiority, open-label, phase 3 trial. Lancet Oncol 2019; 20:352.

Derakhshan F. Reis-Filho JS. Pathogenesis of Triple-Negative Breast Cancer. Annu Rev Pathol 2022; 17: 181-204.

Bane AL, Whelan TJ, Pond GR, Parpia S, Gohla G, Fyles AW, et al. Tumor factors predictive of response to hypofractionated radiotherapy in a randomized trial following breast conserving therapy. Ann Oncol 2014; 25(5): 992-998.

Wang SL, Fang H, Hu C, Song YW, Wang WH, Jin J, et al. Hypofractionated Versus Conventional Fractionated Radiotherapy After Breast-Conserving Surgery in the Modern Treatment Era: A Multicenter, Randomized Controlled Trial from China. J Clin Oncol 2020; 38(31): 3604-3614.

Offersen BV, Alsner J, Nielsen HM, Jakobsen EH, Nielsen MH, Krause M, et al. Hypofractionated Versus Standard Fractionated Radiotherapy in Patients with Early Breast Cancer or Ductal Carcinoma in Situ in a Randomized Phase III Trial: The DBCG HYPO Trial. J Clin Oncol 2020; 38(31): 3615-3625.

Zhang X, Wang X, Chu Y, Zhang L, Meng J, Shi W, et al. Post-mastectomy hypofractionated versus conventionally fractionated radiation therapy for patients receiving immediate breast reconstruction: Subgroup analysis of a phase III randomized trial. Clin Transl Radiat Oncol 2024 26; 50: 100882.

De Matteis S, Facondo G, Valeriani M, Vullo G, De Sanctis V, Ascolese AM, et al. Hypofractionated Radiation Therapy (HFRT) of Breast/Chest Wall and Regional Nodes in Locally Advanced Breast Cancer: Toxicity Profile and Survival Outcomes in Retrospective Monoistitutional Study. Clin Breast Cancer 2022; 22(3): 332-340.

Breast Cancer Atlas n.d. 21 https://www.rtog.org/CoreLab/ ContouringAtlases/BreastCancerAtlas.aspx (accessed August 12, 22 2018)

Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet 2002; 359: 1686-1689.

Baert A, Depuydt J, Van Maerken T, Poppe B, Malfait F, Van Damme T, et al. Analysis of chromosomal radiosensitivity of healthy BRCA2 mutation carriers and non-carriers in BRCA families with the G2 micronucleus assay. Oncol Rep 2017; 37: 1379-1386.

Grosche S, Bogdanova NV, Ramachandran D, Lüdeking M, Stemwedel K, Christiansen H, et al. Effectiveness of hypofractionated and normofractionated radiotherapy in a triple-negative breast cancer model. Front Oncol 2022; 12: 852694.

Jagsi R, Griffith KA, Vicini FA, Abu-Isa E, Bergsma D, Bhatt A, et al. Disease Control After Hypofractionation Versus Conventional Fractionation for Triple Negative Breast Cancer: Comparative Effectiveness in a Large Observational Cohort. Int J Radiat Oncol Biol Phys 2022; 112: 853-860.

Recht A Hypofractionated Whole-Breast Irradiation: Case Closed? J Clin Oncol 2020; 38: 3584-3586.

Lalani N, Voduc KD, Jimenez RB, Levasseur N, Gondara L, Speers C, et al. Breast Cancer Molecular Subtype as a Predictor of Radiation Therapy Fractionation Sensitivity. Int J Radiat Oncol Biol Phys 2021; 109: 281-287.

• PDF

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.